Monoclonal Antibodies Market by Source (Murine, Chimeric, Humanized, and Human), Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others), and End User (Hospitals, Research Institutes, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030

June 2021 | 245 pages | ID: M60F271A8FF8EN
Allied Market Research

Abstracts

The global monoclonal antibodies market was valued at $146,642 million in 2020, and is projected to reach $390,582 million by 2030, registering a CAGR of 10.2% from 2021 to 2030.

Monoclonal antibodies (mAb) are the antibodies which are developed in a laboratory from clone of a single B-cell. These antibodies recognize & attach to a specific receptor present on the surface of cells. The monoclonal antibodies are similar in nature, technically characterized as identical immunoglobulin (Ig). Moreover, these are utilized to detect numerous disease agents and for diagnostic indications. Furthermore, monoclonal antibodies are used in the treatment of autoimmune diseases, inflammatory diseases, infectious diseases, and others.

The growth of the monoclonal antibodies market is driven by rise in prevalence of cancer and other chronic diseases, increase in government funding for cancer research and technology development, and surge in adoption of humanized monoclonal antibodies (mAbs) in the treatment of several diseases including inflammatory, cancer, and autoimmune diseases. In addition, rise in demand for personalized medicines, increase in development of therapeutic monoclonal antibodies, and surge in research collaborations for the development of robust drugs pipeline drives the growth of the market. Moreover, increase in government support in infection control & management, rise in patient awareness regarding applications of murine monoclonal antibodies therapy, increase in number of clinical trials, and introduction of low-priced biosimilar monoclonal antibodies are the other factors that boost the growth of the market. However, poor demand in underdeveloped countries is expected to restrain the growth of the monoclonal antibodies market. Conversely, growth avenues in emerging markets are expected to offer lucrative opportunities during the forecast period.

The monoclonal antibodies market is segmented into source, indication, end user, and region. On the basis of source, the market is categorized into murine, chimeric, humanized, and human. By indication, the market is divided into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others. The cancer segment is further classified into breast cancer, colorectal cancer, lung cancer, ovarian cancer, and others. By end user, the market is fragmented into hospitals, research institutes, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of four regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Source

• Murine
• Chimeric
• Humanized
• Human

By Indication

• Cancer
• Breast cancer
• Colorectal cancer
• Lung cancer
• Ovarian cancer
• Others
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Others

By End User

• Hospitals
• Research Institutes
• Others

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Abbott Laboratories
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Eli Lilly
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis
• Pfizer

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

• Boehringer Ingelheim Pharmaceuticals
• AstraZeneca
• Teva Pharmaceutical Industries

Contents

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
  1.3.1.List of key players profiled in the report
1.4.Research methodology
  1.4.1.Secondary research
  1.4.2.Primary research
  1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings
  3.2.1.Top investment pockets
  3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
  3.5.1.Drivers
    3.5.1.1.Rise in prevalence of various cancer types
    3.5.1.2.Increase in demand of cost-efficient biosimilar monoclonal antibodies
    3.5.1.3.Upsurge in likelihood of epidemic or pandemic outbreaks
  3.5.2.Restraint
    3.5.2.1.Poor demand in underdeveloped countries
  3.5.3.Opportunities
    3.5.3.1.Growth opportunities in emerging markets
  3.5.4.Impact analysis
3.6.Covid-19 Impact analysis on monoclonal antibodies market

CHAPTER 4:MONOCLONAL ANTIBODIES MARKET, BY SOURCE

4.1.Overview
  4.1.1.Market size and forecast
4.2.Murine
  4.2.1.Key market trends, growth factors, and opportunities
  4.2.2.Market size and forecast, by region
  4.2.3.Market analysis, by country
4.3.Chimeric
  4.3.1.Key market trends, growth factors, and opportunities
  4.3.2.Market size and forecast, by region
  4.3.3.Market analysis, by country
4.4.Humanized
  4.4.1.Key market trends, growth factors, and opportunities
  4.4.2.Market size and forecast, by region
  4.4.3.Market analysis, by country
4.5.Human
  4.5.1.Key market trends, growth factors, and opportunities
  4.5.2.Market size and forecast, by region
  4.5.3.Market analysis, by country

CHAPTER 5:MONOCLONAL ANTIBODIES MARKET, BY INDICATION

5.1.Overview
  5.1.1.Market size and forecast
5.2.Cancer
  5.2.1.Market size and forecast, by region
  5.2.2.Market analysis, by country
  5.2.3.Market size and forecast, by type
    5.2.3.1.Breast cancer
      5.2.3.1.1.Market size and forecast
    5.2.3.2.Colorectal cancer
      5.2.3.2.1.Market size and forecast
    5.2.3.3.Lung cancer
      5.2.3.3.1.Market size and forecast
    5.2.3.4.Ovarian cancer
      5.2.3.4.1.Market size and forecast
    5.2.3.5.Others
      5.2.3.5.1.Market size and forecast
5.3.Autoimmune diseases
  5.3.1.Market size and forecast, by region
  5.3.2.Market analysis, by country
5.4.Inflammatory diseases
  5.4.1.Market size and forecast, by region
  5.4.2.Market analysis, by country
5.5.Infectious diseases
  5.5.1.Market size and forecast, by region
  5.5.2.Market analysis, by country
5.6.Others
  5.6.1.Market size and forecast, by region
  5.6.2.Market analysis, by country

CHAPTER 6:MONOCLONAL ANTIBODIES MARKET, BY END USER

6.1.Overview
  6.1.1.Market size and forecast
6.2.Hospitals
  6.2.1.Market size and forecast, by region
  6.2.2.Market analysis, by country
6.3.Research institutes
  6.3.1.Market size and forecast, by region
  6.3.2.Market analysis, by country
6.4.Others
  6.4.1.Market size and forecast, by region
  6.4.2.Market analysis, by country

CHAPTER 7:MONOCLONAL ANTIBODIES MARKET, BY REGION

7.1.Overview
  7.1.1.Market size and forecast
7.2.North America
  7.2.1.Key market trends, growth factors, and opportunities
  7.2.2.Market size and forecast, by country
    7.2.2.1.U.S.
      7.2.2.1.1.U.S. monoclonal antibodies market, by source
      7.2.2.1.2.U.S. monoclonal antibodies market, by indication
      7.2.2.1.3.U.S. monoclonal antibodies market, by end user
    7.2.2.2.Canada
      7.2.2.2.1.Canada monoclonal antibodies market, by source
      7.2.2.2.2.Canada monoclonal antibodies market, by indication
      7.2.2.2.3.Canada monoclonal antibodies market, by end user
    7.2.2.3.Mexico
      7.2.2.3.1.Mexico monoclonal antibodies market, by source
      7.2.2.3.2.Mexico monoclonal antibodies market, by indication
      7.2.2.3.3.Mexico monoclonal antibodies market, by end user
  7.2.3.North America market size and forecast, by source
  7.2.4.North America market size and forecast, by indication
  7.2.5.North America market size and forecast, by end user
7.3.Europe
  7.3.1.Key market trends, growth factors, and opportunities
  7.3.2.Market size and forecast, by country
    7.3.2.1.Germany
      7.3.2.1.1.Germany monoclonal antibodies market, by source
      7.3.2.1.2.Germany monoclonal antibodies market, by indication
      7.3.2.1.3.Germany monoclonal antibodies market, by end user
    7.3.2.2.France
      7.3.2.2.1.France monoclonal antibodies market, by source
      7.3.2.2.2.France monoclonal antibodies market, by indication
      7.3.2.2.3.France monoclonal antibodies market, by end user
    7.3.2.3.UK
      7.3.2.3.1.UK monoclonal antibodies market, by source
      7.3.2.3.2.UK monoclonal antibodies market, by indication
      7.3.2.3.3.UK monoclonal antibodies market, by end user
    7.3.2.4.Italy
      7.3.2.4.1.Italy monoclonal antibodies market, by source
      7.3.2.4.2.Italy monoclonal antibodies market, by indication
      7.3.2.4.3.Italy monoclonal antibodies market, by end user
    7.3.2.5.Spain
      7.3.2.5.1.Spain monoclonal antibodies market, by source
      7.3.2.5.2.Spain monoclonal antibodies market, by indication
      7.3.2.5.3.Spain monoclonal antibodies market, by end user
    7.3.2.6.Rest of Europe
      7.3.2.6.1.Rest of Europe monoclonal antibodies market, by source
      7.3.2.6.2.Rest of Europe monoclonal antibodies market, by indication
      7.3.2.6.3.Rest of Europe monoclonal antibodies market, by end user
  7.3.3.Europe market size and forecast, by source
  7.3.4.Europe market size and forecast, by indication
  7.3.5.Europe market size and forecast, by end user
7.4.Asia-Pacific
  7.4.1.Key market trends, growth factors, and opportunities
  7.4.2.Market size and forecast, by country
    7.4.2.1.Japan
      7.4.2.1.1.Japan monoclonal antibodies market, by source
      7.4.2.1.2.Japan monoclonal antibodies market, by indication
      7.4.2.1.3.Japan monoclonal antibodies market, by end user
    7.4.2.2.China
      7.4.2.2.1.China monoclonal antibodies market, by source
      7.4.2.2.2.China monoclonal antibodies market, by indication
      7.4.2.2.3.China monoclonal antibodies market, by end user
    7.4.2.3.Australia
      7.4.2.3.1.Australia monoclonal antibodies market, by source
      7.4.2.3.2.Australia monoclonal antibodies market, by indication
      7.4.2.3.3.Australia monoclonal antibodies market, by end user
    7.4.2.4.India
      7.4.2.4.1.India monoclonal antibodies market, by source
      7.4.2.4.2.India monoclonal antibodies market, by indication
      7.4.2.4.3.India monoclonal antibodies market, by end user
    7.4.2.5.South Korea
      7.4.2.5.1.South Korea monoclonal antibodies market, by source
      7.4.2.5.2.South Korea monoclonal antibodies market, by indication
      7.4.2.5.3.South Korea monoclonal antibodies market, by end user
    7.4.2.6.Rest of Asia-Pacific
      7.4.2.6.1.Rest of Asia-Pacific monoclonal antibodies market, by source
      7.4.2.6.2.Rest of Asia-Pacific monoclonal antibodies market, by indication
      7.4.2.6.3.Rest of Asia-Pacific monoclonal antibodies market, by end user
  7.4.3.Asia-Pacific market size and forecast, by source
  7.4.4.Asia-Pacific market size and forecast, by indication
  7.4.5.Asia-Pacific market size and forecast, by end user
7.5.LAMEA
  7.5.1.Key market trends, growth factors, and opportunities
  7.5.2.Market size and forecast, by country
    7.5.2.1.Brazil
      7.5.2.1.1.Brazil monoclonal antibodies market, by source
      7.5.2.1.2.Brazil monoclonal antibodies market, by indication
      7.5.2.1.3.Brazil monoclonal antibodies market, by end user
    7.5.2.2.Saudi Arabia
      7.5.2.2.1.Saudi Arabia monoclonal antibodies market, by source
      7.5.2.2.2.Saudi Arabia monoclonal antibodies market, by indication
      7.5.2.2.3.Saudi Arabia monoclonal antibodies market, by end user
    7.5.2.3.South Africa
      7.5.2.3.1.South Africa monoclonal antibodies market, by source
      7.5.2.3.2.South Africa monoclonal antibodies market, by indication
      7.5.2.3.3.South Africa monoclonal antibodies market, by end user
    7.5.2.4.Rest of LAMEA
      7.5.2.4.1.Rest of LAMEA monoclonal antibodies market, by source
      7.5.2.4.2.Rest of LAMEA monoclonal antibodies market, by indication
      7.5.2.4.3.Rest of LAMEA monoclonal antibodies market, by end user
  7.5.3.LAMEA market size and forecast, by source
  7.5.4.LAMEA market size and forecast, by indication
  7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.Abbott Laboratories
  8.1.1.Company overview
  8.1.2.Company snapshot
  8.1.3.Operating business segments
  8.1.4.Product portfolio
  8.1.5.Business performance
8.2.Amgen Inc
  8.2.1.Company overview
  8.2.2.Company snapshot
  8.2.3.Operating business segments
  8.2.4.Product Portfolio
  8.2.5.Business performance
  8.2.6.Key strategic moves and developments
8.3.AstraZeneca PLC.
  8.3.1.Company overview
  8.3.2.Company snapshot
  8.3.3.Operating business segments
  8.3.4.Product Portfolio
  8.3.5.Business performance
8.4.Bayer AG.
  8.4.1.Company overview
  8.4.2.Company snapshot
  8.4.3.Operating business segments
  8.4.4.Product Portfolio
  8.4.5.Business performance
8.5.Eli Lily and Company.
  8.5.1.Company overview
  8.5.2.Company snapshot
  8.5.3.Operating business segments
  8.5.4.Product portfolio
  8.5.5.Business performance
  8.5.6.Key strategic moves and developments
8.6.GlaxoSmithKline plc
  8.6.1.Company overview
  8.6.2.Company snapshot
  8.6.3.Operating business segments
  8.6.4.Product portfolio
  8.6.5.Business performance
  8.6.6.Key strategic moves and developments
8.7.Johnson & Johnson
  8.7.1.Company overview
  8.7.2.Company snapshot
  8.7.3.Operating business segments
  8.7.4.Product portfolio
  8.7.5.Business performance
  8.7.6.Key strategic moves and developments
8.8.Merck & Co., Inc.
  8.8.1.Company overview
  8.8.2.Company snapshot
  8.8.3.Operating business segments
  8.8.4.Product portfolio
  8.8.5.Business performance
8.9.Novartis AG
  8.9.1.Company overview
  8.9.2.Company snapshot
  8.9.3.Operating business segments
  8.9.4.Product portfolio
  8.9.5.Business performance
  8.9.6.Key strategic moves and developments
8.10.PFIZER INC.
  8.10.1.Company overview
  8.10.2.Company snapshot
  8.10.3.Operating business segments
  8.10.4.Product portfolio
  8.10.5.Business performance
  8.10.6.Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 01.MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020-2030 ($MILLION)
TABLE 02.MURINE MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.CHIMERIC MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04.HUMANIZED MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.HUMAN MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06.MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020-2030 ($MILLION)
TABLE 07.MONOCLONAL ANTIBODIES MARKET FOR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 08.MONOCLONAL ANTIBODIES MARKET FOR CANCER, BY TYPE, 2020–2030 ($MILLION)
TABLE 09.MONOCLONAL ANTIBODIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 10.MONOCLONAL ANTIBODIES MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 11.MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2030 ($MILLION)
TABLE 12.MONOCLONAL ANTIBODIES MARKET FOR OTHER INDICATIONS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14.MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 15.MONOCLONAL ANTIBODIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2030 ($MILLION)
TABLE 16.MONOCLONAL ANTIBODIES MARKET FOR OTHER END USER, BY REGION, 2020-2030 ($MILLION)
TABLE 17.MONOCLONAL ANTIBODIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19.U.S. MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 20.U.S. MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 21.U.S. MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 22.CANADA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 23.CANADA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 24.CANADA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.MEXICO MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 26.MEXICO MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 27.MEXICO MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 29.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 30.NORTH AMERICA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 31.EUROPE MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 32.GERMANY MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 33.GERMANY MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 34.GERMANY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 35.FRANCE MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 36.FRANCE MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 37.FRANCE MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.UK MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 39.UK MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 40.UK MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.ITALY MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 42.ITALY MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 43.ITALY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.SPAIN MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 45.SPAIN MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 46.SPAIN MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 48.REST OF EUROPE MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 50.EUROPE MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 51.EUROPE MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 52.EUROPE MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 53.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 54.JAPAN MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 55.JAPAN MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 56.JAPAN MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 57.CHINA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 58.CHINA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 59.CHINA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 63.INDIA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 64.INDIA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 65.INDIA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 67.SOUTH KOREA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 72.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 73.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 74.ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 75.LAMEA MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 76.BRAZIL MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 77.BRAZIL MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 78.BRAZIL MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 80.SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 83.SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 86.REST OF LAMEA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 88.LAMEA MONOCLONAL ANTIBODIES MARKET, BY SOURCE, 2020–2030 ($MILLION)
TABLE 89.LAMEA MONOCLONAL ANTIBODIES MARKET, BY INDICATION, 2020–2030 ($MILLION)
TABLE 90.LAMEA MONOCLONAL ANTIBODIES MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 91.ABBOTT: COMPANY SNAPSHOT
TABLE 92.ABBOTT: OPERATING SEGMENTS
TABLE 93.ABBOTT: PRODUCT PORTFOLIO
TABLE 94.AMGEN: COMPANY SNAPSHOT
TABLE 95.AMGEN: OPERATING SEGMENTS
TABLE 96.AMGEN: PRODUCT PORTFOLIO
TABLE 97.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 98.ASTRAZENECA: BUSINESS SEGMENT
TABLE 99.BAYER: COMPANY SNAPSHOT
TABLE 100.BAYER: BUSINESS SEGMENT
TABLE 101.ELI LILLY: COMPANY SNAPSHOT
TABLE 102.ELI LILLY: OPERATING SEGMENTS
TABLE 103.ELI LILLY: PRODUCT PORTFOLIO
TABLE 104.GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 105.GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 106.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 107.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 108.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 109.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 110.MERCK: COMPANY SNAPSHOT
TABLE 111.MERCK: OPERATING SEGMENTS
TABLE 112.MERCK: PRODUCT PORTFOLIO
TABLE 113.NOVARTIS: COMPANY SNAPSHOT
TABLE 114.NOVARTIS: OPERATING SEGMENTS
TABLE 115.NOVARTIS: PRODUCT PORTFOLIO
TABLE 116.PFIZER: COMPANY SNAPSHOT
TABLE 117.PFIZER: OPERATING SEGMENTS
TABLE 118.PFIZER: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01.MONOCLONAL ANTIBODIES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF MURINE MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF CHIMERIC MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF HUMANIZED MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF HUMAN MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR CANCER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.BREAST CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 19.COLORECTAL CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 20.LUNG CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 21.OVARIAN CANCER MARKET, 2020–2030 ($MILLION)
FIGURE 22.OTHER CANCER TYPE MARKET, 2020–2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 28.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF MONOCLONAL ANTIBODIES MARKET FOR OTHER END USER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 30.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33.NET SALES, 2018–2020 ($MILLION)
FIGURE 34.AMGEN: NET SALES BY DIVISION, 2020 (%)
FIGURE 35.AMGEN: NET SALES BY REGION, 2020 (%)
FIGURE 36.NET SALES, 2018–2020 ($MILLION)
FIGURE 37.ASTRAZENECA REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 38.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.NET SALES, 2018–2020 ($MILLION)
FIGURE 40.BAYER REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 41.BAYER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.NET SALES, 2018–2020 ($MILLION)
FIGURE 43.ELI LILLY REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 44.ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.GLAXOSMITHKLINE: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 47.GLAXOSMITHKLINE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 48.NET SALES, 2018–2020 ($MILLION)
FIGURE 49.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 50.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 51.NET SALES, 2018–2020 ($MILLION)
FIGURE 52.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 53.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 54.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 55.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 56.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 57.PFIZER NET SALES, 2019–2020 ($MILLION)
FIGURE 58.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 59.PFIZER: REVENUE SHARE BY REGION, 2020 (%)